Low immunogenicity of emicizumab in persons with haemophilia A

por Schmitt, Christophe, Emrich, Thomas, Chebon, Sammy, Fernandez, Elena, Petry, Claire, Yoneyama, Koichiro, Kiialainen, Anna, Howard, Monet, Niggli, Markus, Paz‐Priel, Ido, Chang, Tiffany
Publicado 2021

Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis

por Maher, Toby M., Costabel, Ulrich, Glassberg, Marilyn K., Kondoh, Yasuhiro, Ogura, Takashi, Scholand, Mary Beth, Kardatzke, David, Howard, Monet, Olsson, Julie, Neighbors, Margaret, Belloni, Paula, Swigris, Jeffrey J.
Publicado 2021

A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)

por Austin, Cary D., Gonzalez Edick, Melissa, Ferrando, Ronald E., Solon, Margaret, Baca, Miriam, Mesh, Kathryn, Bradding, Peter, Gauvreau, Gail M., Sumino, Kaharu, FitzGerald, J. Mark, Israel, Elliot, Bjermer, Lief, Bourdin, Arnaud, Arron, Joseph R., Choy, David F., Olsson, Julie K., Abreu, Francis, Howard, Monet, Wong, Kit, Cai, Fang, Peng, Kun, Putnam, Wendy S., Holweg, Cécile T.J., Matthews, John G., Kraft, Monica, Woodruff, Prescott G.
Publicado 2020